您的当前位置:首页 > 行业数据 > 奥布替尼用于治疗SLE的IIa期临床试验(NCT04305197)第12周时的SRI-4应答率
图片属性
图片格式:PNG 图片大小:387KB 图片尺寸:2267*934
同报告图片
 / 4
奥布替尼用于治疗SLE的IIa期临床试验(NCT04305197)第12周时的SRI-4应答率_第1页
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
奥布替尼用于治疗SLE的IIa期临床试验(NCT04305197)第12周时的SRI-4应答率_第2页
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
奥布替尼用于治疗SLE的IIa期临床试验(NCT04305197)第12周时的SRI-4应答率_第3页
奥布替尼用于治疗SLE的IIa期临床试验(NCT04305197)第12周时的SRI-4应答率_第4页
奥布替尼用于治疗SLE的IIa期临床试验(NCT04305197)第12周时的SRI-4应答率_第5页
所属报告: 诺诚健华-公司研究报告-血液瘤产品商业化持续推进自免管线进展可喜-240703(50页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠